Independent Surveys Approve Bionovo's Drug for Treatment of Hot Flashes
Posted on: Tuesday, 11 March 2008, 09:01 CDT
Bionovo has reported positive results from two independent physician surveys, which showed that MF101 could become first-line treatment for menopausal vasomotor symptoms or hot flashes.
In both qualitative and quantitative studies, 124 physicians board certified in obstetrics, gynecology and specializing in the treatment of menopause reported MF101, if approved, would be their drug of choice for the treatment of hot flashes. In addition, 92% of physicians reported they would prescribe MF101 before prescribing an antidepressant agent for hot flashes.
Isaac Cohen, chairman and CEO of Bionovo, said: "These independent physician studies provide us with further evidence that if available, MF101 can be a blockbuster drug once it hits the market."
Source: Datamonitor
Related Articles
- Bionovo's MF101 Shows Statistically Significant Improvement in Sleep Disturbance From Hot Flashes
- 'Cool' New Treatment for Hot Flashes in Breast Cancer Survivors
- Depomed Reports Positive Efficacy Data From a Phase 2 Trial of Gabapentin GR(TM) in the Treatment of Menopausal Hot Flashes
- Upsher-Smith Announces Launch of Divigel(R) (Estradiol Gel) 0.1 Percent for Treatment of Moderate to Severe Hot Flashes Associated With Menopause
- Depomed Initiates Dosing of Patients in Phase 2 Trial For Gabapentin GR For the Treatment of Menopausal Hot Flashes
- Depomed Files Investigational New Drug Application for Gabapentin GR for the Treatment of Postmenopausal Hot Flashes
- Hot Flashes often Followed by Insomnia
- Promising Treatment for Hot Flashes Reported in Journal of Palliative Medicine
- FDA to Review Treatment for Hot Flashes
 |
 |
User Comments (0)
RSS Feeds